Page last updated: 2024-10-26

doxapram and Carcinoma, Bronchial

doxapram has been researched along with Carcinoma, Bronchial in 1 studies

Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Romanic, BM1
Lattin, NE1

Other Studies

1 other study available for doxapram and Carcinoma, Bronchial

ArticleYear
Treatment of acute exacerbation of chronic respiratory failure with doxapram: a case report.
    Delaware medical journal, 1985, Volume: 57, Issue:5

    Topics: Aged; Carcinoma, Bronchogenic; Chronic Disease; Combined Modality Therapy; Doxapram; Female; Humans;

1985